Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Por:
Gibert J, Clavé S, Hardy-Werbin M, Taus Á, Rocha P, Longarón R, Piquer G, Chaib I, Carcereny E, Morán T, Salido M, Dalmases A, Bellosillo B and Arriola E
Publicada:
1 feb 2020
Ahead of Print:
5 dic 2019
Resumen:
KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer. However, patients with this driver alteration present heterogeneous clinical outcomes. In this study, we have explored the potential clinical impact of coexisting alterations in this subset of patients.
Filiaciones:
Gibert J:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Clavé S:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
Hardy-Werbin M:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Taus Á:
Medical Oncology Department, Hospital del Mar - CIBERONC, Barcelona, Spain
Rocha P:
Medical Oncology Department, Hospital del Mar - CIBERONC, Barcelona, Spain
Longarón R:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
Piquer G:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
:
Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
:
Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
:
Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Salido M:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
Dalmases A:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
Bellosillo B:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Pathology Department, Hospital del Mar, Barcelona, Spain
Arriola E:
Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
Medical Oncology Department, Hospital del Mar - CIBERONC, Barcelona, Spain
|